Opinion|Videos|December 16, 2024
Expert Insight on Using Dual-IO Regimens for Melanoma in Real-World Practice
Panelists discuss how using dual immunotherapy regimens for melanoma in real-world practice involves balancing efficacy with safety, patient comorbidities, and treatment accessibility, while also addressing challenges such as immune-related adverse events and treatment sequencing.
Advertisement
Episodes in this series
Advertisement
Related to this article
Hashem B. El-Serag, MD, MPH, said HCC risk in MASLD centers on advanced fibrosis and cirrhosis, while extrahepatic cancers warrant routine screening.
More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
Investigators will present detailed findings from a phase 2 study assessing a tambiciclib-based regimen in patients with relapsed/refractory AML at ASH 2026.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths
5